Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/06/24
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024GlobeNewsWire • 02/29/24
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEOGlobeNewsWire • 02/21/24
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024GlobeNewsWire • 01/09/24
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 12/11/23
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)GlobeNewsWire • 11/28/23
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q FilingGlobeNewsWire • 11/24/23
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023GlobeNewsWire • 10/30/23
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023GlobeNewsWire • 10/19/23
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid EpidemicPRNewsWire • 10/16/23
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of DirectorsGlobeNewsWire • 10/02/23
Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?Zacks Investment Research • 09/07/23
Emergent Biosolutions to make Narcan opioid overdose treatment available without prescription starting in SeptemberMarket Watch • 08/30/23
Emergent BioSolutions' NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose EmergencyGlobeNewsWire • 08/30/23